相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
David W. Dodick et al.
CEPHALALGIA (2018)
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine A Randomized Clinical Trial
David W. Dodick et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention A Randomized Clinical Trial
Vladimir Skljarevski et al.
JAMA NEUROLOGY (2018)
Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis
Zsolt Hepp et al.
CEPHALALGIA (2017)
The Idiopathic Intracranial Hypertension Treatment Trial: A Review of the Outcomes
Stacy V. Smith et al.
HEADACHE (2017)
Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines
Joshua M. Cohen et al.
HEADACHE (2017)
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
Stewart Tepper et al.
LANCET NEUROLOGY (2017)
Erenumab (AMG 334) in episodic migraine Interim analysis of an ongoing open-label study
Messoud Ashina et al.
NEUROLOGY (2017)
Fremanezumab for the Preventive Treatment of Chronic Migraine
Stephen D. Silberstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Controlled Trial of Erenumab for Episodic Migraine
Peter J. Goadsby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine
Tiffini Voss et al.
CEPHALALGIA (2016)
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
Hong Sun et al.
LANCET NEUROLOGY (2016)
TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points
Marcelo E. Bigal et al.
NEUROLOGY (2016)
Wiping Out CGRP: Potential Cardiovascular Risks
Antoinette MaassenVanDenBrink et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Therapeutic antibodies against CGRP or its receptor
Marcelo E. Bigal et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
Marcelo E. Bigal et al.
LANCET NEUROLOGY (2015)
Adherence to oral migraine-preventive medications among patients with chronic migraine
Zsolt Hepp et al.
CEPHALALGIA (2015)
Migraine, cardiovascular disease, and stroke during pregnancy: Systematic review of the literature
Ashley Wabnitz et al.
CEPHALALGIA (2015)
Supplement 4: Canadian Guidelines on Parkinson's Disease
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2014)
BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial
Ronald Marcus et al.
CEPHALALGIA (2014)
Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
David W. Dodick et al.
LANCET NEUROLOGY (2014)
Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial
David W. Dodick et al.
LANCET NEUROLOGY (2014)
Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS-II)
Andrew M. Blumenfeld et al.
HEADACHE (2013)
Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society
S. Holland et al.
NEUROLOGY (2012)
Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society
S. D. Silberstein et al.
NEUROLOGY (2012)
Pathophysiology of medication overuse headache: Insights and hypotheses from preclinical studies
Ian D. Meng et al.
CEPHALALGIA (2011)
Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine
David J. Hewitt et al.
CEPHALALGIA (2011)
Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers
Milena De Felice et al.
BRAIN (2010)
Migraine during pregnancy: is it more than a headache?
Stephen A. Contag et al.
NATURE REVIEWS NEUROLOGY (2009)
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial
Tony W. Ho et al.
LANCET (2008)
Calcitonin gene-related peptide receptor antagonist BIBN4096BS for the acute treatment of migraine
J Olesen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Calcitonin gene-related peptide in pregnancy and its emerging receptor heterogeneity
C Yallampalli et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2002)
Infusion of pregnant rats with calcitonin gene-related peptide (CGRP)8-37, a CGRP receptor antagonist, increases blood pressure and fetal mortality and decreases fetal growth
PRR Gangula et al.
BIOLOGY OF REPRODUCTION (2002)
分享论文
